Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Cullinan Therapeutics will host an in-person Immunology Day on June 10, 2026, in New York City to present new clinical data for its autoimmune pipeline. The event will feature initial data from the first multi-dose cohort of CLN-978 in rheumatoid arthritis and single-dose escalation data in systemic lupus erythematosus, building on data previously reported at EULAR 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.